Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05881993 · ClinicalTrials.gov registry record · Early Phase 1

Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects

A Early Phase 1 study of Healthy Volunteer Study, sponsored by Comanche Biopharma.

Completed
Registry status
Early Phase 1
Development phase
45
Enrollment target
1
Study location

NCT05881993 is a Early Phase 1 study of Healthy Volunteer Study that has completed, run by Comanche Biopharma. The registered enrollment target is 45 participants, above the 31-participant average among 9 other Healthy Volunteer Study trials with a reported enrollment target (45% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05881993, a Early Phase 1 study of Healthy Volunteer Study, has completed, sponsored by Comanche Biopharma.

COMPLETED
Registry status
Early Phase 1
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

This is a Phase I, first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and PK of ascending doses of CBP-4888.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG CBP-4888

Study Locations (1)

Texas

  • Comanche Biopharma Clinical Research Site #1 - San Antonio

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2023-05-22
Est. Completion 2024-05-22
Phase Early Phase 1

Sponsor

Comanche Biopharma

1 total trials

What the Registry Record Tells You About NCT05881993

The ClinicalTrials.gov registry entry for NCT05881993 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 31-participant average among 9 other Healthy Volunteer Study trials with a reported enrollment target (45% higher). The listed sponsor is Comanche Biopharma, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteer Study appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05881993 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05881993 about?

NCT05881993 is a clinical study titled "Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects". This is a Phase I, first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and PK of ascending doses of CBP-4888.

What is the current status of trial NCT05881993?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 45 participants. The study started on 2023-05-22. Estimated completion is 2024-05-22.

What conditions does trial NCT05881993 study?

This clinical trial studies the following conditions: Healthy Volunteer Study.

What interventions are being tested in trial NCT05881993?

The interventions under investigation include: Placebo (OTHER), CBP-4888 (DRUG).

Who is sponsoring clinical trial NCT05881993?

This trial is sponsored by Comanche Biopharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05881993 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteer Study

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.